Manila HealthTek is a spinoff company formed to pursue the commercialization of the dengue diagnostic technology developed by a team of UP Manila National Institutes of Health medical researchers led by Dr. Raul Destura.
The efficacy of monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) pathway for treatment of colorectal cancer (CRC) depends on predictive biomarkers that can identify likely responders or non-responders to therapy.
Renieramycin M (RM) is a KCN-stabilized tetrahydroisoquinoline purified from the blue sponge Xestospongia sp., with nanomolar IC50s against several cancer cell lines. Our goal is to evaluate its combination effects with doxorubicin (DOX) in estrogen receptor positive MCF-7 breast cancer cells.
This skill building workshop aims to freely integrate available molecular data from global repositories that are pertinent to locally circulating pathogens and apply it to research areas of interest for both the Biological Threat Reduction Program of the US government thru the Defense Threat Reduction Agency.
Mr. Garrido and Ms. Alcantara shared the preliminary findings of the two Philippine Genome Center’s projects, “Mutational analysis of KRAS, NRAS, PIK3CA, BRAF, and PTEN genes in Filipino Colorectal Cancer Patients,” and “Detection and Functionalization of KRAS, NRAS, PIK3CA, BRAF, and PTEN Gene Mutations in Filipino Colorectal Cancer Patients,” through poster presentations.
The Biotek-M™ Dengue Aqua Kit is a diagnostic test designed to detect dengue infections in serum/plasma samples.
Dr. Garcia did postdoctoral work in New Zealand (University of Otago Medical School), Paris (Hopital de la Pitie-Salpetriere/Universite Pierre et Marie Curie), the United States (Case Western Reserve University School of Medicine) and London (University College London), before being appointed senior research scientist at Cancer Research UK’s Beatson Institute in Scotland. He has worked on Merck- and Roche-funded projects involving characterization of drug targets for pain and development of drug screening assays for disrupting cellular proliferation in cancer, respectively.
She obtained her doctoral degree at the Kobe University Graduate School of Medicine, Kobe, Japan where she did work on the molecular basis of Glucose-6-Phosphate dehydrogenase deficiency (1) and of Maple Syrup Urine Disease (MSUD) among clinically diagnosed Filipino patients (2).
Dr. Eva Maria C. Cutiongco-de la Paz is the Vice Chancellor for Research, University of the Philippines (UP) Manila and the Executive Director of the National Institutes of Health.
Dr. Salvana is a multi-awarded and internationally recognized scientist, physician, and HIV/AIDS advocate who returned to the Philippines under the Balik (Returning) Scientist Program of the Department of Science and Technology to work on tropical medicine and other local infectious diseases.